ライフサイエンスコーパス: DTC

1 DTC advertising for health services increased from $542

2 DTC cell lines established from the bone marrow of patie

3 DTC extravasation into the bone marrow may be encouraged

4 DTC is rare but frequently results in graft loss and dea

5 DTC prescription drug advertising increased from $1.3 bi

6 DTC spending on advertising for laboratory tests (such a

7 DTC status identifies high-risk patients after FEC chemo

8 DTCs persist in distant tissues despite systemic adminis

9 DTCs were detected in 9.9% of the patients, but not asso

10 DTCs were immunostained with the pan-keratin antibody A4

11 tion study in Koreans using a total of 1,085 DTC cases and 8,884 controls, and validated these result

12 CTCs, whereas in 13 of 76 patients (17.1%), DTCs could be detected.

13 ccess and third-party tool usage among 1,137 DTC customers recruited through social media.

14 Of the 15 DTCs, 6 were renal cell cancer; 5, lung cancer; 2, lymph

15 responses for 62 clinical encounters from 16 DTC telemedicine websites from February 4 to March 11, 2

16 We studied the mechanisms of ziram's (a DTC fungicide) neurotoxicity in vivo.

17 We propose that a DTC analysis may be a sensitive method for assessing the

18 amine this system, we first tested thiram, a DTC pesticide known to display neurotoxic effects, obser

19 Of 1,066 patients with a DTC result at BM2 and available follow-up information (m

20 uced from dithiocarbamate-type accelerators (DTCs) or thiuram-type accelerators (thiurams) during the

21 ting in the field and patients with advanced DTC/MTC now have new standard-of-care therapy options.

22 articipants may not be representative of all DTC PGT consumers.

23 ificant difference between the SUVmax of all DTCs and PDTCs, regardless of BRAF mutational status (P

24 ks were colocalized with massively amplified DTC transposons (CACTA family) in euchromatin, which may

25 gh-risk patients after FEC chemotherapy, and DTC monitoring status after secondary treatment with doc

26 This is the first study analyzing CTC and DTC status in 1 cohort of nonmetastatic patients with EC

27 rvival was observed between DTC-negative and DTC-positive patients and was evident in subgroup analys

28 eas concordant results (DTC/CTC negative and DTC/CTC positive) were found in 54 patients (71.1%).

29 ry reconstruction analysis of bulk tumor and DTC genomes enables ordering of CNA events in molecular

30 In only 3 patients (3.9%), CTCs and DTCs were detected simultaneously, whereas concordant re

31 ained from the clinical analyses of CTCs and DTCs, which demonstrate that the animal models mimic, in

32 orphologically classified as tumor cells are DTCs disseminating from the observed tumor.

33 The hydrodynamic sizes of Au DTCs were estimated by diffusion nuclear magnetic resona

34 The structure and property of the Au DTCs are studied to probe two effects: the entropy gain

35 At baseline, DTCs were detected in 26 of 60 patients in the zoledroni

36 log-rank test) survival was observed between DTC-negative and DTC-positive patients and was evident i

37 iting integrin-mediated interactions between DTCs and the PVN, driven partly by endothelial-derived v

38 marker will be expressed on every CTC or BM-DTC throughout disease progression (giving high sensitiv

39 ial markers to accurately detect CTCs and BM-DTCs is associated with difficulties, and prostate-speci

40 marrow-derived disseminated tumour cells (BM-DTCs) can offer clinically relevant biological insights

41 very 3 weeks) were administered, followed by DTC analysis 1 and 13 months after the last docetaxel in

42 DO oxidation with subsequent ring opening by DTC salts, which can be generated in situ from secondary

43 and glycogen metabolism could be altered by DTCs.

44 ent of the glycogenolytic activity of bGP by DTCs such as thiram may be a new mechanism by which cert

45 ne-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 y

46 th metastatic differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

47 ood tests for differentiated thyroid cancer (DTC) have been introduced into routine clinical practice

48 Differentiated thyroid cancer (DTC) incidence has been reported to have increased three

49 incidence of differentiated thyroid cancer (DTC) is increasing.

50 th metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroid-stimulating ho

51 I) therapy in differentiated thyroid cancer (DTC) patients requiring a completion treatment after lob

52 treatment in differentiated thyroid cancer (DTC) patients.

53 tastases from differentiated thyroid cancer (DTC) using (131)I WB imaging and (124)I PET.

54 ility loci of differentiated thyroid cancer (DTC) were identified by previous genome-wide association

55 ients who had differentiated thyroid cancer (DTC) with that of a matched general population.

56 ems exist for differentiated thyroid cancer (DTC), but all harbor limitations.

57 management of differentiated thyroid cancer (DTC), taking into consideration the methodological conce

58 Differentiated thyroid cancer (DTC), with a rapidly increasing incidence is the most co

59 I)-refractory differentiated thyroid cancer (DTC).

60 metastasized differentiated thyroid cancer (DTC); identify suitable treatment regimens, taking into

61 ed with the graft (donor-transmitted cancer [DTC]) or develop subsequently from the graft (donor-deri

62 accepting units and di(tert-butyl)carbazole (DTC) as the electron-donating units.

63 pediatric differentiated thyroid carcinoma (DTC) is excellent.

64 astases in differentiated thyroid carcinoma (DTC) patients with elevated serum thyroglobulin and both

65 Differentiated thyroid carcinoma (DTC), as one of the major component cancers of CS, is th

66 ients with differentiated thyroid carcinoma (DTC).

67 in the canonical C. elegans distal tip cell (DTC) germ stem cell niche mediated by previously unobser

68 pathway signaling from the distal tip cell (DTC) niche to the germline maintains the progenitor pool

69 ate is specified by somatic distal tip cell (DTC) niche-germline GLP-1 Notch signaling through repres

70 lled mesenchymal niche, the distal tip cell (DTC), employs GLP-1/Notch signaling and an RNA regulator

71 vulval precursor cells, the distal tip cell (DTC), intestine, and the lateral hypodermal seam cells b

72 cellular protrusions of the distal tip cell (DTC), the germline stem cell niche in the gonad.

73 ling cascade in the gonadal distal tip cell (DTC), the germline stem cell niche, where it negatively

74 s strikingly similar to the distal tip cell (DTC)-germ stem cell niche.

75 ate of these early disseminated tumor cells (DTC) remains elusive.

76 e from the pool of disseminated tumor cells (DTC) that survive adjuvant or neoadjuvant therapy, and p

77 er harbor a myriad disseminated tumor cells (DTC) throughout the body, most of which are found as mit

78 Disseminated tumor cells (DTC), which share mesenchymal and epithelial properties,

79 ular properties of disseminated tumor cells (DTC).

80 two specialized C. elegans distal tip cells (DTCs) provide an in vivo model system for the study of d

81 rmined by migration of the distal tip cells (DTCs).

82 ic significance of disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in 1 cohort of

83 r cells (CTCs) and disseminated tumor cells (DTCs) are increasingly recognized for their potential ut

84 r cells (CTCs) and disseminated tumor cells (DTCs) in bone marrow (BM) in patients with colorectal li

85 The presence of disseminated tumor cells (DTCs) in bone marrow (BM) predicts survival in early bre

86 These dormant disseminated tumor cells (DTCs) may reside in close proximity to osteoblasts, whil

87 These disseminated tumor cells (DTCs) may resist therapy and lay dormant or progress to

88 ing the seeding of disseminated tumor cells (DTCs) to bone, the survival of DTCs and microscopic meta

89 Disseminated tumor cells (DTCs) undergo a dormant state in the distant metastatic

90 al for sterilizing disseminated tumor cells (DTCs), it is critical to determine the contribution of b

91 rences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain quiescent

92 d on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuva

93 The presence of disseminated tumour cells (DTCs) in bone marrow is predictive of poor metastasis-fr

94 an originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivatio

95 2016-2018, shelters, drug treatment centers (DTCs), AIDS organizations, and Federally Qualified Healt

96 iram may be a new mechanism by which certain DTCs exert their neurotoxic effects.

97 We show that chemoresistant DTCs occupy the perivascular niche (PVN) of distant tiss

98 nitial studies, the detection of circulating DTC cells by thyrotropin receptor (TSHR) mRNA measuremen

99 tastasis while EMT6-tumor bearing mice clear DTCs shed from primary tumors as well as those introduce

100 to synthesize dithiol-protected Au clusters (DTCs).

101 ort (ETC) and the definitive therapy cohort (DTC).

102 h to counseling a patient who is considering DTC testing to learn more about his ancestry and his ris

103 st rapid increase was in direct-to-consumer (DTC) advertising, which increased from $2.1 billion (11.

104 the way for clinical and direct-to-consumer (DTC) applications.

105 In the direct-to-consumer (DTC) context, where raw data are often made available to

106 asing public interest in direct-to-consumer (DTC) genetic ancestry testing has been accompanied by gr

107 but is available through direct-to-consumer (DTC) genetic testing companies.

108 Direct-to-consumer (DTC) genetic testing for disease susceptibility is large

109 Direct-to-consumer (DTC) genetic testing has attracted a great amount of att

110 atients choosing to have direct-to-consumer (DTC) genetic testing without involving their clinicians

111 Direct-to-consumer (DTC) genetics services are increasingly popular, with te

112 able developments in the direct-to-consumer (DTC) genomic testing arena, in particular with regard to

113 Direct-to-consumer (DTC) personal genomic testing (PGT) allows individuals t

114 to big-data methods and direct-to-consumer (DTC) strategies.

115 ity of rapidly expanding direct-to-consumer (DTC) telemedicine websites and smartphone apps diagnosin

116 e to malpractice risk in direct-to-consumer (DTC) telemedicine, this study reviews the LexisNexis leg

117 meet the needs of all persons contemplating DTC genetic testing.

118 N-1 is required cell-autonomously to control DTC migration.

119 y, and in parallel to ced-10/Rac, to control DTC pathfinding.

120 n where it acts cell-autonomously to control DTC turning.

121 A days to criterion (DTC) analysis was used to determine delays in acquisitio

122 The clinical application of CTC/DTC requires better understanding of the biological mech

123 underwent a modified diurnal tension curve (DTC) 1 week before the TSST, with 3 IOP measurements per

124 ces the role of MIG-15 in integrin-dependent DTC turning.

125 d not receive zoledronic acid had detectable DTCs (p=0.054).

126 t was the number of patients with detectable DTCs at 3 months.

127 juvant therapy, and patients with detectable DTCs following therapy are at substantially increased ri

128 y tests the ability of TSHR mRNA to diagnose DTC preoperatively and to detect cancer recurrence.

129 ing kinase (NIK) works with MIG-38 to direct DTC turning as shown by mig-38 RNAi with the mig-15(rh80

130 posure to the commonly used dithiocarbamate (DTC) pesticides is associated with an increased risk of

131 Dithiocarbamates (DTCs) are important industrial chemicals used extensivel

132 Dithiocarbamates (DTCs) were recently discovered as carbonic anhydrase (CA

133 ich were also analysed for dithiocarbamates (DTCs) using a spectrophotometric method.

134 icle, we evaluate glycosyl dithiocarbamates (DTCs) with unprotected C2 hydroxyls as donors in beta-li

135 used in the production of dithiocarbamates (DTCs), which are potent fungicides and pesticides, thus

136 n vivo, growth arrest or survival of dormant DTCs is interrupted in different organs.

137 tored the proliferation of otherwise dormant DTCs, enabling these cells to efficiently colonize forei

138 deaths in 11 cases) as opposed to late DTC (DTC-related deaths in 3 of 4 cases).

139 126) indicate that CACN-1 is required during DTC migration for proper pathfinding and for cessation o

140 Early DTC (diagnosed </=6 weeks of transplantation) showed a b

141 Forty-eight DTC and 34 PDTC patients who underwent (18)F-FDG PET/CT

142 Identifying therapies that eliminate DTCs and/or effectively target cells transitioning to pr

143 s is a viable clinical strategy to eradicate DTCs and prevent metastasis.

144 tantially from 1997 through 2016, especially DTC advertising for prescription drugs and health servic

145 new factors with prognostic implications for DTC.

146 This emphasizes the potential for DTC analysis as a surrogate marker for adjuvant treatmen

147 potential risk stratification predictors for DTC.

148 ivary gland dysfunction during follow-up for DTC patients receiving high-activity radioiodine treatme

149 mRNA >1 ng/mug had 96% predictive value for DTC, whereas 95% of patients with undetectable mRNA and

150 f 72 docetaxel-treated patients analyzed for DTCs after treatment, 15 (20.8%) had persistent DTCs.

151 Four DTC patients at MedStar Washington Hospital Center were

152 TC, were suspected of having metastasis from DTC (e.g., elevated thyroglobulin level without thyroglo

153 Glycosyl DTC couplings are highly beta-selective despite the abse

154 Glycosyl DTCs are readily activated with Cu(I) or Cu(II) triflate

155 pot conversion of glycals into beta-glycosyl DTCs via DMDO oxidation with subsequent ring opening by

156 analyzed 2,428 consecutive patients who had DTC and underwent treatment from 1965 to 2013 at the Dep

157 rom 2006 to 2010 recruiting patients who had DTC, were suspected of having metastasis from DTC (e.g.,

158 Overall 120 (32.4%) patients harbored DTC in their bone marrow.

159 However, DTCs also have recognized medicinal use in the treatment

160 first evidence that the UPR is activated in DTC in the bone marrow from cancer patients, warranting

161 Several new factors that may be involved in DTC risk stratification have emerged, such as thyroid st

162 rial of VEGF-targeted therapy (sorafenib) in DTC were presented in June 2013, and two phase III trial

163 evelopment of targeted systemic therapies in DTC and MTC in the past 5 years is incredibly exciting i

164 In DTCs isolated from bone marrow specimens from breast can

165 ell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant dise

166 tic programmes of quiescence and survival in DTCs.

167 Colocating testing in DTCs and treatment in FQHCs provided key LTC venues to a

168 gy and reported the prevalence of incidental DTC (iDTC).

169 med to estimate the prevalence of incidental DTC in published autopsy series and determine whether th

170 Pharmaceutical companies increased DTC marketing about diseases treated by their drugs with

171 employ distinct signaling pathways to induce DTC dormancy in bone.

172 mosensitization is achieved without inducing DTC proliferation or exacerbating chemotherapy-associate

173 ntegrated experimental system to investigate DTCs in bone marrow and identify combination therapy aga

174 factors, treatment, and outcome of juvenile DTC.

175 initial treatment for patients with juvenile DTC.

176 lated deaths in 11 cases) as opposed to late DTC (DTC-related deaths in 3 of 4 cases).

177 ase diagnosis and treatment provided by many DTC telemedicine websites.

178 redifferentiation treatment for metastasized DTC.

179 d dosimetry for (131)I therapy of metastatic DTC when the same patient was prepared with and imaged a

180 ion methods for (131)I therapy of metastatic DTC.

181 If one or more DTCs were present at BM2, six cycles of docetaxel (100 m

182 These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FDG-avid than BRAF-WT

183 ive (18)F-FDG PET/CT in radioiodine-negative DTC patients with elevated and rising thyroglobulin.

184 dose) in 15 consecutive radioiodine-negative DTC patients with elevated and rising thyroglobulin.

185 transplantation) showed a better outcome (no DTC-related deaths in 11 cases) as opposed to late DTC (

186 nced relapse) compared with patients with no DTCs after treatment (adjusted hazard ratio, 7.58; 95% C

187 The docetaxel-treated patients with no DTCs after treatment had comparable DFI (8.8% experience

188 rienced relapse) compared with those with no DTCs both at BM1 and BM2 (12.7% experienced relapse; P =

189 for proper pathfinding and for cessation of DTC migration at the end of larval morphogenesis.

190 e use of (131)I in patients with evidence of DTC after lobectomy.

191 Given the expansion of DTC genetic tests, this study highlights the need for fu

192 hose depletion by RNAi results in failure of DTC turning so that DTCs continue their migration away f

193 toxic bystander effects in delayed growth of DTC xenografts.

194 eir services, the possible adverse impact of DTC genetic testing on healthcare systems, and concern a

195 To dissect the mechanism of DTC turning, we examined the role of a novel gene, F40F1

196 Significantly more foci of metastases of DTC may be identified in patients prepared with THW than

197 A comprehensive picture of DTC PGT consumers who shared their results with a health

198 The presence of DTC in bone marrow is a strong and independent prognosti

199 Presence of DTC significantly correlated with aggressive tumor biolo

200 everal suggestions to improve the quality of DTC telemedicine websites and apps and avoid further gro

201 a genome-wide RNAi screen for regulators of DTC migration.

202 rospective study the prognostic relevance of DTC in bone marrow for the natural postoperative course

203 iovascular disease, 39 (7.4%) as a result of DTC, and 39 (7.4%) as a result of other/unknown causes.

204 rly differentiated and oxyphilic subtypes of DTC.

205 In terms of DTC genomic testing for disease susceptibility, most of

206 n the classic scheme of initial treatment of DTC.

207 In long-term follow-up of DTC patients with thyroglobulin antibodies, 96% with und

208 thermore, we identified specific variants of DTC that have different effects according to cancer type

209 ns indicate that the proliferative arrest of DTCs is attributable, in part, to the syndecan-mediated

210 gene NANOG, which contributes to dormancy of DTCs in the bone marrow.

211 assume that this is because the majority of DTCs are quiescent.

212 This indicates that the majority of DTCs fail, for still unknown reasons, to initiate rapid

213 rovide evidence that the microenvironment of DTCs protects them from chemotherapy, independent of cel

214 Recent research using animal models of DTCs and CTCs have provided novel insights into these pr

215 The molecular nature of DTCs remains elusive, as well as when and from where in

216 quencing to identify and trace the origin of DTCs in breast cancer.

217 the subsequent surrogate marker potential of DTCs for outcome determination.

218 Presence of DTCs in BM was determined by immunocytochemistry using p

219 e host parenchyma prevented proliferation of DTCs that had recently infiltrated foreign tissue by bin

220 or progression, and clinical significance of DTCs and CTCs are controversially discussed in the liter

221 tumor cells (DTCs) to bone, the survival of DTCs and microscopic metastases under dormancy, and the

222 behind tumor dissemination, the survival of DTCs, and their activation to aggressive growth from dor

223 mechanistic evidence that bGP is a target of DTCs.

224 have been identified as potential targets of DTCs in the brain, the molecular mechanisms underlying t

225 This study explores the use of DTCs for identification of patients insufficiently treat

226 further insight into the prognostic value of DTCs for metastatic organotropisms.See related article b

227 of zoledronic acid may be through effects on DTCs.

228 Fifty-one DTC patients (32 girls and 19 boys; </= 20 y old; mean a

229 For all other DTC patients, regardless of age or TNM stage, no signifi

230 No other DTCs or thiurams were detected.

231 s after treatment, 15 (20.8%) had persistent DTCs.

232 A positive DTC genetic test result that might change clinical manag

233 marker in the surveillance of TgAb-positive DTC patients.

234 tional candidate genes of CS and potentially DTC, we analysed a multi-generation CS-like family with

235 h talin and the MIG-15/NCK-1 complex promote DTC motility and that MIG-38 may act as a negative regul

236 nse activity in patients with RAI-refractory DTC who experienced disease progression while taking pri

237 Yet how Axl regulates DTC proliferation in marrow remains undefined.

238 Patients with remaining DTCs had markedly reduced DFI (46.7% experienced relapse

239 e marrow mesenchymal stem cells to represent DTCs in a bone marrow niche.

240 of demographics, participation in research, DTC tests ordered, and testing motivations.

241 simultaneously, whereas concordant results (DTC/CTC negative and DTC/CTC positive) were found in 54

242 and Monte Carlo dosimetry modeling revealed DTCs both within and beyond the range of the alpha-parti

243 for patients with low- to intermediate-risk DTC requiring completion treatment after lobectomy due t

244 The use of rhTSH in patients with low-risk DTC undergoing thyroid remnant ablation appears to have

245 refractory differentiated thyroid cancer (RR-DTC).

246 ed patients with histologically confirmed RR-DTC stratified by age (</= 65 or > 65 years).

247 for treatment of patients of any age with RR-DTC.

248 ascular cell adhesion molecule 1, sensitizes DTCs to chemotherapy.

249 Several DTC genealogy services allow users to upload genetic dat

250 Some DTC tests for genetic susceptibilities look for only a f

251 is a powerful approach to identify and study DTCs, yielding insight into metastatic processes.

252 However, the mechanisms supporting DTC survival are poorly understood.

253 CTCs were disclosed with CellSearch System, DTC with immunocytology.

254 try, including privacy issues, ensuring that DTC companies provide accurate information about the ris

255 Ai results in failure of DTC turning so that DTCs continue their migration away from the midbody regi

256 atients (BLBLI, 72; carbapenem, 31), and the DTC included 174 (BLBLI, 54; carbapenem, 120).

257 of germ cell divisions were observed at the DTC-Sh1 interface.

258 pairs of daughter cells oriented between the DTC and Sh1, and Sh1 grew over the Sh1-facing daughter.

259 The "distal pool" is maintained by the DTC in an essentially uniform and immature or "stem cell

260 mparing IOP measurements obtained during the DTC and immediately after TSST.

261 25 bp DAF-3 binding element required for the DTC lag-2 reporter response to the environment and to DA

262 4% for the ETC and 9.3% versus 16.7% for the DTC, respectively (P > .2, log-rank test).

263 ative zone cells that are displaced from the DTC niche.

264 DSL ligand family member, is produced in the DTC and activates the GLP-1/Notch receptor on adjacent g

265 In the DTC cohort, 24 tumors harbored a BRAF(V600E) mutation, w

266 ignaling promotes expression of lag-2 in the DTC in a daf-3-dependent manner.

267 by RNAi to cofilin and Arp2/3 perturbed the DTC-Sh1 interface, reduced germ cell proliferation, and

268 Consumer satisfaction with the DTC PGT experience; whether and, if so, how many results

269 Within the DTC group, TSH level was predictive for cardiovascular m

270 mportant for integrin activation, causes the DTCs to stop migration prematurely.

271 Strong expression of CACN-1 in the DTCs, and data from cell-specific RNAi depletion experim

272 lar pseudo-time and traced the origin of the DTCs to either the main tumor clone, primary tumor subcl

273 rithiocarbonate, structurally related to the DTCs, were prepared by reaction of alcohols/thiols with

274 mordium, and expression continues throughout DTC migration where it acts cell-autonomously to control

275 ic and molecular alterations contributing to DTC survival.

276 rted cases of medical malpractice related to DTC telemedicine services or their health care professio

277 f any studies that have examined response to DTC genetic testing for ancestry or for drug response.

278 Ultimately, DTC genomic testing for common markers and conditions is

279 526), postoperatively in patients undergoing DTC follow-up (n = 418) and in patients monitored for kn

280 nors (0.06%): 3 were DDC (0.01%) and 15 were DTC (0.05%).

281 71.9 months from the time of BM2), 7.2% were DTC positive.

282 viduals, although it remains unclear whether DTC genomic information will still be attainable.

283 3, FHIT, SEPT11 and SLC24A6) associated with DTC.

284 sociation of autoimmune thyroid disease with DTC is less clear.

285 sociation of autoimmune thyroid disease with DTC, the prognostic significance of TgAb positivity and

286 One hundred patients with DTC (19.1%) died, 22 (4.2%) as a result of cardiovascula

287 y Cox regression analyses; 524 patients with DTC and 1,572 sex- and age-matched controls from a large

288 [IQR], 4.1 to 15.9 years) for patients with DTC and 10.5 years (IQR, 9.9 to 10.9 years) for controls

289 Patients with DTC had an increased risk of cardiovascular and all-caus

290 Furthermore, patients with DTC may benefit from assessment and treatment of cardiov

291 of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had

292 In patients with DTC, elevated TSHR mRNA levels became undetectable in al

293 ause mortality is increased in patients with DTC, independent of age, sex, and cardiovascular risk fa

294 adioiodine ablation therapy in patients with DTC.

295 Over 70% of the samples were positive, with DTC present in 46.5%, lambda-cyhalothrin in 37.1%, and o

296 survival was 83% for kidney recipients with DTC compared with 93% for recipients without DTC (P=0.07

297 Of 15 recipients, 3 (20%) recipients with DTC died as a direct consequence of cancer.

298 Recipients with DTC underwent explant/excision (11), chemotherapy (4), a

299 d in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery.

300 DTC compared with 93% for recipients without DTC (P=0.077).